Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence - Quiz - MDSpire

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence

  • By

  • Zeng-Yi Huang

  • Jialiang Chen

  • Boman Zhu

  • Xiao-Lian Liu

  • April 30, 2026

  • 0 min

Share

Original Source(s)

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence

  • by Zeng-Yi Huang, Jialiang Chen, Boman Zhu, Xiao-Lian Liu

  • April 30, 2026

Related Content

Romiplostim N01 Enhances Platelet Recovery in Autologous Stem Cell Transplantation with Non-Cryopreserved Peripheral Blood Stem Cells for Plasma Cell Disorders

Short-term cardiotoxicity and early echocardiographic changes following autologous hematopoietic stem cell transplantation: a single-center retrospective analysis

Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT